Why Prostate Lesion Size Matters for Staging and Treatment

The size of a lesion on a prostate MRI is one of the plainest clues doctors have to how far a cancer has gone and what it will take to treat it. It feeds into almost every later decision, from how worrying the scan is rated to whether you can be monitored, have a targeted treatment, or keep the nerves during surgery. But a lesion on MRI is usually a shadow of the real tumour, often smaller than what the pathologist later finds, so size works as one signal among several, not a final answer.

What the Size Numbers on Your MRI Report Mean

Your report may give a PI-RADS score from 1 to 5, the radiologist’s rating of how likely a lesion is to be a cancer that needs treatment. The score is not a single measurement. The radiologist combines several image types, and which one carries the most weight depends on where the lesion sits. In the outer zone, the diffusion-weighted images (which show how freely water moves in the tissue) usually count most, while in the inner zone the standard T2 images matter most.

The main lesion, which your report may call the index lesion, is usually the most suspicious spot, and its longest width is reported in millimetres. Size enters the score mainly as a tie-breaker. A lesion that already looks very suspicious is moved from PI-RADS 4 to PI-RADS 5 when it reaches 15 mm or more.¹ Testing other cut-offs, such as 14 mm, gave almost no better results than 15 mm.² So a lesion can score high because of how it looks even when it is small.

A PI-RADS score rates suspicion from images, and only a biopsy confirms cancer. Even at PI-RADS 5, not every large lesion turns out to be significant cancer.³ A large lesion raises the odds, but some prove benign or low grade, and the biopsy grade usually matters more than size when choosing treatment.

A typical size line lists the zone (often peripheral or transition), the size, and the score. Sizes may be given in millimetres for width, or in cc or ml for volume. Volume is calculated from three measurements rather than the longest width alone, so a lesion with a modest width can still have a meaningful volume if it is thick in other directions. If several lesions are listed, ask which one is the index lesion.

Smaller lesions still count. Among PI-RADS 4 lesions checked by biopsy, those over about 8.5 mm were about twice as likely to be significant cancer as smaller ones.⁴ Yet significant and harmless lesions differed by only about 1 mm in typical size, 11 mm versus 10 mm.⁵

Does a Bigger Lesion Mean a More Aggressive Cancer

Doctors grade how aggressive prostate cancer looks under a microscope using the Gleason grade group, from 1 (slow) to 5 (most aggressive). In men who had the prostate removed, larger tumour width went along with higher PSA, higher PI-RADS scores, and higher Gleason scores.⁶ Higher PI-RADS scores, which partly reflect size, also matched higher-risk results on a genetic tumour test.⁷

Size and grade answer different questions. Size describes how much tumour is visible on the scan, while grade describes how abnormal the cells look and how fast they are likely to behave. A small lesion with a high grade can be more dangerous than a larger one with a low grade, so a small size is not automatically reassuring. Doctors combine size, grade, and PSA to place a man in a risk group, and that group guides treatment more than any one number.

Location changes what size means. Size predicts significant cancer better for lesions in the outer zone of the prostate than in the inner transition zone.⁸ The size that signals concern is about 14 mm in the outer zone but about 21 mm in the inner zone.⁹ That is because inner-zone cancers are often found larger and with higher PSA, yet end up no more aggressive overall.¹⁰ A 16 mm inner-zone lesion may therefore be less worrying than the same size in the outer zone.

Size alone also does not set the stage. Stage describes whether cancer has left the prostate, so a large lesion contained inside the gland can still be an early stage, and a report can describe an aggressive-looking cancer that is still confined. Size matters for stage mainly because bigger lesions are more likely to reach the edge.

How Size Signals Spread Beyond the Prostate

Spread beyond the prostate wall raises the cancer to stage 3. The capsule is the thin outer layer of the prostate, and radiologists may report capsular contact, how many millimetres of the lesion touch that outer edge.¹¹ Each extra millimetre of contact raised the odds of spread by about 13% in one study.¹² Contact of about 6 to 7 mm was the best single line for flagging any spread.¹³

This measurement caught more spread than a radiologist’s overall impression, and radiologists agreed with each other more often using it.¹⁴ Other signs radiologists look for include a bulging or irregular edge and changes in the tissue just outside the gland.

It also flags some men whose cancer had not actually spread.¹⁵ A lesion can touch the edge for a long stretch and still be contained. If contact length appears on your report, treat it as a warning sign, not proof that the cancer has escaped. Surgery, where the pathologist examines the removed gland, usually confirms the true stage, and sometimes more imaging is used first. You can ask your urologist how contact length changes your surgery plan.

Spread matters because confined cancer has more treatment options, including focal therapy. Spread may lead to wider surgery or to hormone therapy added to radiation, and it affects whether the nerves can be safely spared.

Size and Your Options for Monitoring or Focal Therapy

Active surveillance means watching a low-risk cancer with regular PSA tests, MRIs, and biopsies instead of treating it right away. Men with grade group 2 cancer may still be suitable for surveillance when the MRI lesion is under 15 mm, even with many positive biopsy cores.¹⁶ That is because MRI size predicted bad findings and return of cancer after surgery better than the number of positive cores did.¹⁷

PSA is checked regularly, typically every few months at first. A repeat MRI compares the lesion’s size and appearance with earlier scans. A repeat biopsy is done if the scan or PSA changes, and many programs also schedule one at set intervals. Treatment is offered if the cancer shows signs of progressing.

Focal therapy destroys only the tumour area, often with heat from ultrasound, to protect urinary and sexual function. Expert agreement says visible tumours under 1.5 ml are suitable, and up to 3 ml if confined to one side.¹⁸ Tumours taking up under about 20% of the prostate are also considered suitable.¹⁹ One ultrasound treatment program required lesions under 20 mm across, PSA of 20 or less, and no grade 5 pattern.²⁰ The treated zone needs a safety margin of about 5 to 10 mm around the tumour, which is why bigger tumours are harder to fit.²¹ If your lesion sits near a cut-off, ask whether a repeat scan or second reading would change your eligibility, and how your grade group and PSA weigh against size.

How Size Shapes Surgery and Radiation

A positive surgical margin means cancer cells reach the edge of the removed tissue. Men with positive margins had lesions with about 13 mm of edge contact versus about 5.5 mm without.²² Lesions over 15 mm were more common on sides with positive margins, as were lesions near the tip of the prostate.²³ Surgeons can plan to take a little more tissue where the MRI shows a lesion near the edge, balanced against nerve preservation.

Size can also help the other way. In high-risk cancer on one side, a lesion of 15 mm or less with no spread on MRI marked a group with about a 5% rate of spread to the other side.²⁴ Surgeons can then more safely spare the nerves for erections on that side. It is worth asking whether each side can be spared given the lesion’s size and location, since partial sparing is sometimes possible. The trade-off is between erection recovery and cancer control.

Positive margins over 3 mm roughly doubled the chance of PSA coming back.²⁵ Even so, a positive margin does not mean the cancer will definitely return, because many men with one never have a rise in PSA.

In radiation therapy, the visible MRI lesion is often outlined and given an extra dose.²⁶ The boost area is usually widened by 0 to 5 mm around the visible lesion.²⁷

Why MRI Measurements Aren’t Exact

MRI usually shows prostate tumours smaller than they turn out to be on the removed gland.²⁸ In one group, the true tumour was larger in 19 of 22 men.²⁹ On some MRI views, tumours appeared about half their real volume.³⁰ Cancer cells at the fringe of a tumour can be spread thinly through normal tissue, which does not show up as a clear shape. The radiologist draws a line around what looks abnormal, which tends to follow the dense core rather than the faint edges.

Small cancers are often missed altogether. MRI found about 70% of cancers 1 cm or larger but only about 1 in 5 smaller ones.³¹ Cancers below about 1 cm are hard to tell apart from normal variation in prostate tissue, and low-grade cancers are less likely to be seen than high-grade ones. A scan that shows nothing therefore does not rule out all cancer, which is why a negative scan is usually followed by PSA monitoring, and sometimes biopsy, if suspicion remains.

Readers differ too. When different radiologists measured the same lesions, their numbers straddled the 15 mm line in 7 of 20 men.³² One reading can place you on either side of a cut-off.

A second opinion is worth asking about if your size sits near 15 mm or a focal therapy limit. Specialist prostate radiologists read many scans each year, and it helps to bring the original images, not just the report.

What It Means If Your Lesion Grows

On surveillance, progression on MRI includes a higher suspicion score or a doubling of lesion volume.³³ Lesions typically grow about 18 to 23% a year, similar for grade groups 1 and 2.³⁴

When a follow-up MRI shows growth, the radiologist compares the new scan with your earlier one, measuring the same lesion and checking whether its score has changed. A repeat biopsy is often the next step, because growth alone does not show whether the cancer has become more aggressive. Options are then discussed, which may include continuing surveillance, or starting treatment if the biopsy shows a higher grade.

Keeping your own record makes comparisons easier. Keep copies of each report, note the lesion size, score, and date, and ask whether the scans used the same scanner and centre.